Georges JOURDI

In untreated chronic lymphocytic leukemia, fixed-duration venetoclax-based regimens were noninferior to continuous ibrutinib with regard to 3-year progression-free survival and were associated with higher MRD-negative rates. Full phase 3 CLL17 trial results and Research Summary: nejm.org/doi/full/10.10…

If you attended #ISTH2025, you may have had the chance to hear about the COBRRA trial during our late-breaking research session! COBRRA is the FIRST head to head trial of apixaban vs rivaroxaban in the management of acute VTE. Read the article here: nejm.org/doi/full/10.10…

In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period. Full COBRRA trial results: nejm.org/doi/full/10.10…

The @ISTH #SSC Subcom. on Platelets in Health & Disease is conducting a project to identify crit. patterns & mgmt strat. that may inform future care GLs for adult Glanzmann Thrombasthenia (GT) patients w/art. thromb. events. Learn more & particiate at: bit.ly/4lqAWyJ

@2Scottish @edelyn_park Congrats @2Scottish 🎉

Top poster award. Really appreciate all the international scientists giving ⁦@edelyn_park⁩ feedback on her PhD work in Washington DC. So much accomplished, so much to do for the cures of tomorrow. #PhDLife.

BREAKING from @NEJM In cancer patients w/ Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) is : 🔘Noninferior to full-dose (5 mg BID) for VTE recurrence 🔘Lower bleeding risk (12.1% vs. 15.6%) 🔘Safer extended anticoagulation, same protection. #Thrombosis #cancer @OncoAlert @Cihan_Ay_MD DOI: 10.1056/NEJMoa2416112

Thanks @SFTHemostase!!

Le prochain congrès @SFTHemostase sera a Lyon, organisé par les équipes de Lyon et de Genève, du 1er au 3 octobre 2025 !

AntiXI dans le cancer, une présentation très claire par le Pr @LaurentBertole1 ! @SFTHemostase #hemostase #thrombose #CFH2024

La masterclass Flux continue avec Benoit Ho-Tin-Noé sur la modélisation de la thromboinflammation veineuse. #thrombose #sfth #flux

Mercredi 11 septembre au #CFH2024 c'est la Masterclass Thromboprophylaxie périopératoire avec Stéphanie Roullet et Thomas Quemeneur! @SFTHemostase #hemostase

Mercredi 11 septembre au #CFH2024 c'est la masterclass Modèles d'étude de l'hémostase et de la thrombose en flux avec Benoit Ho-Tin-Noé et Pierre Mangin! @SFTHemostase #hemostase #thrombose

Esteemed colleague and leader in the field of hemostasis, Pr Nigel Key will be our guest of honor for the 2024 congress of the French Society of Hemostasis and Thrombosis @SFTH #CFH2024 @cfh_2024 We are very much looking forward to his keynote lecture on tranexamic acid

📣 Le #CFH2024 c'est dans 2 semaines! On n'oublie pas de s'inscrire 👉bit.ly/CFH2024inscrip… Petits conseils pour la valise : on pense au ☂ et 👟 adaptées en prévision d'une éventuelle drache 🌧

Le vendredi 13 septembre au #CFH2024 c’est l’occasion d’écouter Yacine Boulaftali expliquer le rôle des plaquettes dans l’hémorragie cérébrale et dans la formation et la rupture des anévrismes. On aurait tord de rater cette session ! @SFTHemostase @la_SFNV #hemostase #plaquettes

Let the show begin!

So proud of you Martine! #isth2024 @isth @SFTHemostase 🇹🇭🇫🇷🎊

The French Society of Thrombosis and Haemostasis @SFTHemostase has a stand at #ISTH2024 !! Please stop and say bonjour!!

Join us at the French Society on Thrombosis and Hemostasis corner to talk Frenchie and learn more about us! #isth2024 @SFTHemostase @isth 🇫🇷🇹🇭😍